Vascular Medicine is a premier academic journal for researchers and practitioners in the field of cardiovascular health, published by SAGE Publications Ltd. With an ISSN of 1358-863X and E-ISSN 1477-0377, this esteemed journal has been at the forefront of publishing quality research since its inception in 1992, with convergence extending to 2024. Ranked in the Q2 category for both Cardiology and Cardiovascular Medicine as well as for miscellaneous Medicine in 2023, it is recognized for its significant contributions to advancing knowledge and clinical practice within these domains. Its Scopus ranking situates it at #91 out of 387 in the field, reflecting its high impact and the relevance of its published research, which is crucial for addressing the challenges in vascular health today. Although it is not an open-access journal, Vascular Medicine remains dedicated to disseminating vital findings that bridge the gap between research and clinical application, making it an essential resource for medical researchers, healthcare professionals, and students alike.

The JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, published by SAGE PUBLICATIONS INC, is a premier resource in the fields of cardiology and pharmacology, with an impressive impact factor reflective of its significant contributions to the scientific community. Established in 1996 and continuing through 2024, this journal is indexed in Scopus, achieving notable rankings, including Q2 in both Cardiology and Cardiovascular Medicine and Pharmacology. By fostering a multidisciplinary approach, it aims to improve pharmaceutical therapies and patient outcomes in cardiovascular health. Although not an open-access journal, it provides various subscription options to grant access to its cutting-edge research and reviews. As a vital platform for meaningful discourse and innovation in cardiovascular pharmacology, the journal attracts a diverse readership of researchers, professionals, and students, enhancing knowledge and advancing the field.

Frontiers in Cardiovascular Medicine is a leading open-access journal published by FRONTIERS MEDIA SA, dedicated to advancing research in the field of cardiology and cardiovascular medicine. Since its inception in 2014, the journal has become a vital platform for the dissemination of high-quality research, boasting a commendable Q2 rank in the 2023 category for Cardiology and Cardiovascular Medicine. With a focus on promoting innovative studies and clinical insights, Frontiers in Cardiovascular Medicine facilitates open access to its content, allowing researchers, healthcare professionals, and students from around the globe to engage with the latest findings which are critical for the advancement of cardiovascular health. The journal's significant presence in the academic landscape, as indicated by its Scopus ranking (161/387 and 58th percentile), underscores its importance as a research outlet in this essential field. Located in Lausanne, Switzerland, the journal continues to support the global cardiovascular community by encouraging collaboration and knowledge sharing to address the challenges faced in cardiovascular medicine today.

Clinica e Investigacion en Arteriosclerosis is a premier academic journal dedicated to the field of cardiology and cardiovascular medicine, published by ELSEVIER. With its ISSN 0214-9168 and E-ISSN 1578-1879, the journal aims to disseminate high-quality research and innovations in the understanding and treatment of arterial diseases, contributing significantly to both clinical practices and pharmacological advancements. Established in 2007 and continuing into 2024, the journal has garnered recognition with a notable Q3 categorization in both Cardiology and Cardiovascular Medicine and Pharmacology (medical) for 2023, reflecting its impact in the academic community. Researchers and healthcare professionals utilizing this journal will find a diverse range of articles exploring novel therapeutic strategies and epidemiological data, making it an essential resource for advancing knowledge and practice in cardiovascular health. While it does not operate as an open-access journal, the findings published in Clinica e Investigacion en Arteriosclerosis are pivotal for understanding current trends and future directions in cardiovascular research.

IJC Heart & Vasculature is a premier open-access journal published by Elsevier Ireland Ltd, dedicated to advancing research in the fields of cardiology and cardiovascular medicine. Since its inception in 2013, this journal has established itself as a valuable resource for clinicians, researchers, and students keen on exploring the latest developments in heart and vascular health. With an impressive impact factor and ranked within Q2 in its category (2023), IJC Heart & Vasculature has achieved a significant Scopus rank of #125 out of 387, placing it in the 67th percentile of cardiology journals. The journal not only emphasizes high-quality research but also promotes innovative studies that can shape clinical practices and improve patient outcomes. Researchers and professionals can access a plethora of peer-reviewed articles, original research, and comprehensive reviews that unravel the complexities of cardiovascular science. With a commitment to fostering open and impactful dialogue in the field, IJC Heart & Vasculature is poised to be an essential platform for knowledge exchange in the evolving landscape of cardiovascular research.

International Heart Journal, published by INT HEART JOURNAL ASSOC, serves as a pivotal platform for research and discourse in the fields of cardiology and cardiovascular medicine. With its ISSN 1349-2365 and E-ISSN 1349-3299, this esteemed journal is based in Japan and is located at the University of Tokyo, Graduate School of Medicine, Department of Cardiovascular Medicine. Since its inception in 2005, International Heart Journal has blossomed into a respected publication with an impact factor that signifies its growing relevance, ranking in the Q3 category of both cardiology and miscellaneous medicine as of 2023. This journal not only disseminates vital research findings but also fosters collaboration among researchers and healthcare professionals. Notable for its Open Access options, it ensures the availability of its content to a broader audience, thereby enhancing knowledge transfer and innovation in cardiovascular care. With an ongoing commitment to improve clinical practice and patient outcomes, the journal continues to be an essential resource for those dedicated to advancing the understanding of heart health and disease.

Netherlands Heart Journal is a premier academic publication dedicated to advancing knowledge in the field of cardiology and cardiovascular medicine. Published by BOHN STAFLEU VAN LOGHUM BV, this journal has established itself as a critical platform for researchers, professionals, and students seeking to explore groundbreaking findings and innovative practices in cardiovascular health. With an ISSN of 1568-5888 and E-ISSN 1876-6250, the journal boasts a respectable Q2 ranking in the Cardiology and Cardiovascular Medicine category, placing it in the top half of its field according to the 2023 quartiles. The Scopus ranking places it 130th out of 387 in the relevant category, indicating a commendable percentile rank of 66th, which attests to its influence and quality of published research. Spanning from 2005 to 2024, the journal endeavors to include a diverse array of topics, encompassing clinical practice, technological innovations, and public health considerations related to cardiovascular diseases. Researchers and practitioners are encouraged to engage with the journal's robust content, contributing to and benefiting from the collaborative effort to enhance cardiovascular health worldwide.

CARDIOVASCULAR DRUGS AND THERAPY, published by Springer, is a premier journal dedicated to the latest advances in cardiovascular pharmacology and therapeutics. With a significant impact factor and esteemed rankings in cardiology and pharmacology, this journal is positioned in the top quartile categories, reflecting its influence and contribution to the field. Since its inception in 1987, the journal has served an international audience, providing a platform for researchers and practitioners to publish high-quality original research, critical reviews, and innovative clinical studies that address pressing issues in cardiovascular health. The journal's rigorous peer-review process ensures the utmost scholarly merit, making it an essential resource for professionals aiming to stay at the forefront of cardiovascular drug research and therapy. While not an open-access publication, it is widely available through institutional subscriptions, enhancing its reach within the global community of cardiology researchers and practitioners. Located in the Netherlands, CARDIOVASCULAR DRUGS AND THERAPY continues to play a vital role in advancing our understanding of cardiovascular diseases and the pharmacological solutions available to combat them.

Journal of Atherosclerosis and Thrombosis is a leading academic publication dedicated to advancing research in the fields of cardiovascular medicine, biochemistry, and internal medicine. Published by the Japan Atherosclerosis Society, this esteemed journal operates from its headquarters in Tokyo, Japan, and has been a vital resource in its area since its inception in 1994. With its robust impact in Cardiology and Cardiovascular Medicine, ranking in the top quartile (Q1) as of 2023, and a commendable standing in Internal Medicine and Biochemistry, the journal fosters an environment of innovation and discovery, showcasing significant studies and advancements that shape clinical practices and therapeutic approaches. Though not an open-access publication, it offers a wealth of insights to researchers, professionals, and students seeking to deepen their understanding of atherosclerosis and thrombosis. By continually featuring high-quality articles, the Journal of Atherosclerosis and Thrombosis plays an essential role in bridging the gap between research and practice, facilitating critical conversations that influence the future of cardiovascular health.

Diabetes & Vascular Disease Research is a leading academic journal dedicated to advancing the understanding and treatment of cardiovascular and metabolic diseases, particularly diabetes. Published by SAGE Publications Ltd in the United Kingdom, this journal serves as a key resource for researchers, clinicians, and students seeking to explore the intricate relationship between diabetes and vascular health. With an impressive Impact Factor and ranked in the Q2 quartile in prominent categories such as Cardiology, Endocrinology, and Internal Medicine, the journal provides a platform for high-quality, peer-reviewed research. Covering a broad range of topics from pathophysiology to therapeutic innovations, Diabetes & Vascular Disease Research plays a vital role in shaping contemporary discourse in the field. With contributions from leading experts and a commitment to disseminating valuable findings, this journal is a must-read for anyone involved in the fight against vascular complications arising from diabetes.